Treatment of hepatitis C with interferon-alpha and ribavirine in a patient with long-term clozapine treatment.
Liukkonen
Timo
T
Sorjonen
Mirja
M
Jokelainen
Jari
J
Timonen
Markku
M
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000633:toxicity*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000633:toxicity*; D003024:Clozapine / Q000008:administration & dosage / Q000633:toxicity*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000633:toxicity*; D007958:Leukocyte Count; D008297:Male; D011092:Polyethylene Glycols; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000523:psychology; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000633:toxicity*
D014150:Antipsychotic Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; D003024:Clozapine